Navigation Links
CVBT Opens Two Additional Sites for Patient Enrollment for Phase II Heart Trial
Date:12/11/2008

LAS VEGAS, Dec. 11 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) announced today that two additional hospitals in the United States opened for patient enrollment for its ACORD Phase II clinical trial for the treatment of severe coronary heart disease. The sites are Minneapolis Heart Institute Foundation in Minneapolis MN, and Princeton Baptist Medical Center in Birmingham AL.

Mercy Hospital Fairfield (Ohio) and The Christ Hospital in Cincinnati, Ohio were first to open for enrollment in early September, and are working in collaboration to screen and treat patients in the trial.

CVBT now has three sites open for patient enrollment.

About CardioVascular BioTherapeutics

CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the ACORD trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the legs. An additional study is being conducted in patients with chronic back pain who may have perfusion defects to their spine. For more information about CardioVascular BioTherapeutics, Inc. please visit www.cvbt.com.

About The ACORD Trial

CVBT's ACORD (Angiogenesis for the treatment of CORonary heart Disease) trial for the treatment of severe coronary heart disease will include four randomized, double-blind, placebo-controlled doses in approximately 120 patients with severe coronary heart disease. Thirty sites are expected to participate.

    Media Contact:
    Allison Caplan,
    CardioVascular BioTherapeutics, Inc.
    (702) 839-7200, acaplan@cvbt.com

    Investor Contact:
    Amy Montano Gordon,
    CardioVascular BioTherapeutics, Inc.
    (702) 839-7220, investorrelations@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
2. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
3. New Risk Gene for Rheumatoid Arthritis and Lupus Opens Door to More Effective Treatments
4. Global HIV Vaccine Enterprise Names Alan Bernstein as Inaugural Executive Director, Opens New Secretariat
5. PPD Opens Offices in Sydney, Australia; Copenhagen, Denmark; Lima, Peru; and Lisbon, Portugal
6. Pilot Study Opens the Door for Avastin Use in Curative Setting for Women With Breast Cancer
7. Medpace Opens Clinical Pharmacology Unit in Cincinnati, Ohio
8. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
9. EDICT Opens Public Comment Period for Clinical Trials Policy Recommendations
10. Meditrina Pharmaceuticals, Inc. Opens Investigational New Drug (IND) Application for Phase IIb Clinical Trial With MPI-676 in Endometriosis
11. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... Research and Markets has announced the addition of the ... report to their offering. ... The Global Endoscopy Market is poised to grow ... reach approximately $47.6 billion by 2025. This industry ... segments on global as well as regional levels presented in the ...
(Date:2/23/2017)... YORK , February 23, 2017 ... in the United States . According to ... the cannabis industry is expected to create 283,422 jobs by ... percent compounded over the next four years. The accelerating pace ... drives the growth of legal cannabis market, which will further ...
(Date:2/23/2017)... 23, 2017 Persistence Market ... global market for intraoperative imaging, excerpts from which ... US$ 513.9 million. According to the report, the ... the grounds of increasing adoption of minimally-invasive surgeries ... diagnostic imaging for neurosurgeries. The world,s leading medical ...
Breaking Medicine Technology:
(Date:2/23/2017)... , ... February 23, 2017 , ... HealthPostures, the desk ... an expert sit stand solutions representative to the Minneapolis Home and Garden Show which ... the event that is garnering national attention is the Minneapolis Convention Center. , ...
(Date:2/22/2017)... New York (PRWEB) , ... February 22, 2017 ... ... floor entrance and lobby of a new healthcare contact center in Georgia, PENETRON ... , One of the nation’s largest healthcare systems recently invested $51 million to ...
(Date:2/22/2017)... Tampa, Fla. (PRWEB) , ... February 22, 2017 ... ... the field of regenerative medicine in recent years. The technology is so cutting ... sanction regulations on the protocol for stem cell procedures. However, successful patient outcomes ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... and eligibility requirements effective with the April 2017 testing period. NACCM, a nonprofit ... “The Care Manager Certified (CMC) exam is periodically re-calibrated to ensure that newly ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... to accurately understand each Medicare Advantage member’s risk, identify any gaps-in-coding, as ... new solution helps transform the HCC Risk Adjustment process from a typical ...
Breaking Medicine News(10 mins):